Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333824 | 0.91 | NPSR1 (0.68) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL334043 | 0.86 | PTGES (0.61) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333454 | 0.86 | MEN1 (0.74) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333699 | 0.85 | MAPT (0.61) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333995 | 0.85 | USP14 (0.53) | TSHRNPSR1KMT2AMEN1PTGES | |
| SCHEMBL333920 | 0.84 | KMT2A (0.57) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333953 | 0.84 | KMT2A (0.60) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333739 | 0.83 | KMT2A (0.62) | TSHRNPSR1KMT2AMEN1GAA | |
| SCHEMBL333865 | 0.83 | ALOX5 (0.44) | TSHRNPSR1KMT2AMEN1ALOX5 | |
| SCHEMBL333757 | 0.82 | KMT2A (0.56) | TSHRNPSR1KMT2AMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | TSHR 1377/4885NPSR1 144/4885KMT2A 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.